ACC 2024: Panel Discussion Principal Results From The RELIEVE-HF Trial
During the panel discussion, the author and the team were congratulated for conducting a sham-controlled, randomized, double-blind trial, which challenges existing notions by demonstrating a lack of efficacy in heart failure treatment. Unlike previous trials, this trial excluded extremely low wedge patients and did not require elevated filling pressures at rest or with exertion. Despite presumably sicker patients with reduced ejection fraction (EF), this trial revealed lower filling pressures compared to former trials. The trial showed a wedge around 15-16, while in reduced left atrial pressure (LAP) heart failure, it was 35. Additionally, the LA to RA gradient was only six, whereas in former trials, it was about 17. Furthermore, the right ventricle (RV) appeared lower, while transpulmonary artery pressures (TAPCs) and pulmonary vascular resistance (PVR) were higher in this study compared to previous ones.
The discussion raised questions regarding the inclusion criteria of elevated pulmonary capillary wedge pressure as a threshold and its potential role in the lack of efficacy, particularly in heart failure with reduced EF versus preserved EF. Dr. Boskert noted significant differences between the reduced LAP HF2 trial and their trial, highlighting that the former required an exercise-induced increase in pulmonary capillary wedge pressure. Despite similar baseline wedge pressures, Relieve-HF enrolled a much sicker patient population with higher natriuretic peptide levels and reduced six-minute walk distance, leading to different outcomes. This disparity may explain the harmful trends observed in preserved EF patients in their trial compared to the reduced EF patients in the LAP HF2 trial.
The discussion focused on examining hard endpoints, particularly mortality, in patients with different types of heart failure. Researchers sought to understand the specific causes of death in these patients, comparing outcomes between those with reduced ejection fraction (REF) and preserved ejection fraction (PEF). They found that most deaths were cardiovascular-related, with an increase in deaths attributed to heart failure or sudden events in patients with preserved ejection fraction. Additionally, the presence of a shunt had varying effects, particularly in those with reduced filling pressures.
The speaker addresses speculation about the size of the shunt hole in the context of cardiovascular physiology. They note that the size of the orifice, in this case, five millimetres, differs from other shunts like the reduced LAP shunt, which has an eight-millimetre orifice. The speaker explains that larger orifices can lead to exponential increases in blood flow with rising left atrial pressure, resulting in a QP/QS ratio of around 1.2 to 1. Mechanistic differences observed on echocardiography explain how hearts with reduced ejection fraction remained compliant and tolerated the shunt's blood flow. Conversely, hearts with preserved ejection fraction became non-compliant, leading to adverse effects such as increased RV and IVC size, elevated pulmonary artery pressure, and decreased cardiac output, highlighting the importance of shunt size in different patient populations.
the presentation highlighted promising findings regarding the safety and efficacy of shunts, particularly in patients with heart failure with reduced ejection fraction (HFREF) and possibly elevated pulmonary capillary wedge pressure. These data suggest that shunts could be a beneficial therapy for HFREF patients who remain symptomatic despite optimal medical treatment. However, caution is advised regarding the use of shunts in patients with heart failure with preserved ejection fraction (HFpEF) based on the criteria used in the trial. Future trials will likely incorporate these insights to further evaluate the potential of shunts as a treatment option for HFREF patients.
American College of Cardiology (ACC) Congress 2024, 6th April – 8th April 2024, Atlanta, Georgia, USA.



